Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Lauren I Aronson, Emma L Davenport, Serena G Giuntoli, Muralikrishnan Srikanth, Emma Smith, Gareth J Morgan, MD, PhD, Faith Davies

Blood (2010) 116 (21): 4083.

https://doi.org/10.1182/blood.V116.21.4083.4083

Published: 2010

Journal Articles

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

Tina Bagratuni, Ping Wu, David Gonzalez de Castro, Emma L. Davenport, Nicholas J. Dickens, Brian A. Walker, Kevin Boyd, David C. Johnson, Walter Gregory, Gareth J. Morgan, Faith E. Davies

Blood (2010) 116 (2): 250–253.

https://doi.org/10.1182/blood-2010-01-263236

Published: 2010

Journal Articles

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Emma M Smith, PhD, Brian A Walker, PhD, Emma L Davenport, PhD, Lauren I Aronson, BSc.Hons., David Krige, PhD, Leon Hooftman, MD, Alan Drummond, PhD, Gareth J Morgan, MD, PhD, Faith Davies, MD

Blood (2009) 114 (22): 607.

https://doi.org/10.1182/blood.V114.22.607.607

Published: 2009

Journal Articles

XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.

Tina Bagratuni, Ping Wu, David Gonzalez de Castro, Emma L Davenport, Brian A Walker, Matthew W Jenner, David C Johnson, Gareth J. Morgan, Faith E Davies

Blood (2008) 112 (11): 1686.

https://doi.org/10.1182/blood.V112.11.1686.1686

Published: 2008

Journal Articles

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

Faith E. Davies, MD, Hannah E. Moore, Emma L. Davenport, PhD, Alan S. Dunlop, Srikanth Muralikrishnan, David Krige, PhD, Leon Hooftman, MD, Gareth Morgan, PhD

Blood (2007) 110 (11): 2505.

https://doi.org/10.1182/blood.V110.11.2505.2505

Published: 2007

Journal Articles

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Emma L. Davenport, Hannah E. Moore, Alan S. Dunlop, Swee Y. Sharp, Paul Workman, Gareth J. Morgan, Faith E. Davies

Blood (2007) 110 (7): 2641–2649.

https://doi.org/10.1182/blood-2006-11-053728

Published: 2007

Includes: Supplemental data

Journal Articles

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Emma L. Davenport, PhD, Hannah Moore, BSc, Alan Dunlop, BSc, Paul Workman, PhD, Gareth J. Morgan, MD, PhD, Faith E. Davies, MD

Blood (2006) 108 (11): 848.

https://doi.org/10.1182/blood.V108.11.848.848

Published: 2006

NARROW

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.

Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma.

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only